Background: Hormone receptor status in human breast cancer cells is a strong indicator of the aggressiveness of a tumor. Triple negative breast cancers (TNBC) are aggressive, difficult to treat, and contribute to high incidences of metastasis by possessing characteristics such as increased tumor cell migration and a large presence of the transmembrane protein, cluster of differentiation 44 (CD44) on the cell membrane. Estrogen receptor-positive (ER+) cells are less aggressive and do not migrate until undergoing an epithelial-mesenchymal transition (EMT). Methods: The relationship between EMT and CD44 during metastatic events is assessed by observing changes in EMT markers, tumor cell detachment, and migration following cytokine treatment on both parental and CD44 knockdown human breast tumor cells. Results: ER+ T47D and MCF-7 human breast cancer cells treated with OSM demonstrate increased CD44 expression and CD44 cleavage. Conversely, ER-MDA-MB-231 human breast cancer cells do not show a change in CD44 expression nor undergo EMT in the presence of OSM. In ER+ cells, knockdown expression of CD44 by shRNA did not prevent EMT but did change metastatic processes such as cellular detachment and migration. OSMinduced migration was decreased in both ER+ and ER-cells with shCD44 cells compared to control cells, while the promotion of tumor cell detachment by OSM was decreased in ER+ MCF7-shCD44 cells, as compared to control cells. Interestingly, OSM-induced detachment in ER-MDA-MB-231-shCD44 cells that normally don't detach at significant rates. Conclusion: OSM promotes both EMT and tumor cell detachment in ER+ breast cancer cells. Yet, CD44 knockdown did not affect OSM-induced EMT in these cells, while independently decreasing OSM-induced cell detachment. These results suggest that regulation of CD44 by OSM is important for at least part of the metastatic cascade in ER+ breast cancer.
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Background
The primary cause of mortality in patients with breast cancer is not from the primary tumor itself but its metastasis. [1] [2] [3] [4] Continued studies addressing breast cancer metastasis are important for improved patient survival and to gain a better understanding of the multitude of events that take place during metastatic disease.
In order for tumor cells to metastasize they must undergo a phenotypic change known as an epithelial-mesenchymal transition (EMT), which allows for the intravasation of the tumor cell into a nearby blood vessel or lymphatic channel. [5] [6] [7] Once
Inflammatory cytokines of the interleukin-6 (IL-6) family such as oncostatin M (OSM) have been shown to be important in driving tumor invasion and metastasis. 21 OSM is a pleiotropic, IL-6-family cytokine, which is important in inflammation exhibited during breast tumor development. [22] [23] [24] Tumor cells, as well as monocytes, macrophages, and neutrophils, secrete OSM. 25 OSM activates the JAK/STAT, MAPK, and PI3K/AKT pathways via binding its receptors, OSM receptor beta (OSMRβ) or leukemia inhibitory factor receptor beta (LIFRβ), each dimerized with a common gp130 subunit. 21, 26, 27 Our previous data and data from the literature have shown that OSM inhibits proliferation of breast cancer cells, while increasing metastatic capacity. 28, 29 OSM causes EMT, cell detachment, migration, and an overall increase in tumor cell aggressiveness. Proteins and events involved in breast tumor metastasis are directly affected by OSM signaling, which creates a more aggressive phenotype through the upregulation of proteins such as CD44. Cluster of differentiation 44 (CD44) is a transmembrane protein involved in cell adhesion and migration after it undergoes cleavage from proteolytic activity. 30 Standard CD44 (CD44s) is roughly 80-85 kDa depending on post-translational modifications. [31] [32] [33] CD44 contains a carboxy-terminal portion known as the cytoplasmic tail and an amino-terminal portion outside the membrane, folded together by post-translational glycosylation. 34, 35 CD44 is a major receptor for binding hyaluronic acid (HA) in the extracellular matrix, 36, 37 and it binds HA by its stem region that is directly above the surface of the membrane and includes domains derived from alternatively spliced exons. 38, 39 Alternatively spliced CD44, such as CD44v6 has been found in multiple cancers types including gastric and head and neck carcinoma. 40, 41 Depending on the structure of CD44 with its multiple combinations of exons, signaling differs based on how it is recognized by an upstream ligand. 42, 43 The varying roles of CD44 raises the complexity while studying the protein. 51 Regardless of the combination of exons comprising CD44v, exons from the CD44s remain present despite alternative splicing.
52
As the metastatic process begins, CD44 expression is upregulated and CD44 protein is cleaved, which correlates within the same time frame that EMT takes place. 53 EMT and the upregulation of CD44 have been shown to be involved together in breast tumor metastasis. [54] [55] [56] The correlation between EMT and CD44 during metastasis has been shown as the standard form of CD44 becomes the dominant form of the CD44 protein while EMT takes place. 57 The direct association and timing of EMT and cellular detachment has yet to be linked to CD44 expression. CD44s and CD44v have been shown to be strong biomarkers commonly found in higher percentages of more aggressive tumor populations, 58 that are assumed to have previously undergone EMT. Although both CD44 and EMT are implicated in breast tumor progression and metastasis, establishing a direct connection between the two has proved to be challenging. A connection between CD44 and tumor progression exists as high CD44 expression is considered to be hallmark for breast cancer stem cells (BCSCs). Cancer stem cells pose a challenge during treatment as they are capable of controlled cell proliferation. 59 CD44
expression is an important marker for a BCSC identification within a diverse population of tumor cells. 60 The most common BCSC population studied in human breast cancer is CD44 + /CD24 low/-. Metastasis occurs though EMT, cellular detachment, migration and potentially BCSCs evading common therapeutic treatment.
In this study, we demonstrate a connection between OSM-induced metastatic events and CD44 during tumor cellular detachment and migration. Both EMT and CD44 have been linked to metastasis, but there has been a question as to whether they are directly or indirectly associated. Here, we provided data showing that OSM induces EMT and upregulates CD44 expression, but that OSMinduced EMT is independent of CD44. Conversely, we show that CD44 plays a very specific role in OSM-induced detachment and migration, both important events in the metastatic cascade that follows EMT. Furthermore, CD44 knockdown in aggressive ER-TNBC cells contributed to the cells behaving as a less aggressive (ER+-like) cell during detachment. These findings delineate another important mechanism by how OSM induces breast cancer metastatic potential.
Materials and methods
Cell culture and cytokine stimulation MCF7 and T47D ER+ luminal A human breast cancer cells were obtained directly from the American Type Culture Collection (Rockville, MD), maintained in RPMI-1640 media supplemented with 10% fetal bovine serum (FBS) and 100 U/mL each of penicillin and streptomycin. Cells were maintained at 37°C, 5% carbon dioxide, and 95% humidity. All media and supplements were obtained from Hyclone (Logan, UT). Human oncostatin M (OSM) (Peprotech, Rocky Hill, NJ) was added at 25 ng/mL. 61 Table 1 . ΔΔCq method was used for analyzation of the data as described by Livak and Schmittgen. 63 Statistical analysis was performed using GraphPad Prism software for 1 way ANOVA tests. Lysates were run on a 7.5-10% SDS-PAGE gel and transferred to a nitrocellulose membrane. Immunoblot analysis was performed using primary antibodies for human E-cadherin (1:2000), β-actin (1:5,000), α-catenin (1:2,500) (Cell Signaling Secondary, Danvers, MA), CD44 (1:5000) (kindly provided by Dr. Liliana Mellor and Dr. Knudson). Antibodies were HRP-conjugated donkey anti-rabbit (1:5,000). 
Flow cytometry

shRNA transduction
Gene knockdown of CD44 and a non-targeting control was conducted using shERWOOD shRNA lentiviral constructs (Transomic Technologies, Huntsville, AL). Viral transduction of MDA-MB-231 luc and MCF-7 luc cells was performed according to manufacturer's protocol. Puromycin was used for initial selection followed by fluorescence microscopy to isolate transduced cell population. CD44 expression was confirmed by Western blot analysis.
Detachment assay
A Detachment assay was used to compare relative tumor cell detachment in the presence or absence of recombinant OSM (25 ng/mL). Cells were plated at 10,000 cells per well in a 24-well plate and allowed to attach overnight. Once plated, cells were placed in 1% FBS RPMI media for 4 hrs without treatment. After a 4 hr incubation, cells were then treated with or without OSM in 1% media for the allotted time (1, 3, or 5 days). To assess detached cells, media was collected and centrifuged. The pellets were resuspended in equal parts of RPMI media and Trypan Blue. Detached cells were then counted. Cells stained with Trypan blue were excluded from the counts. Proliferation was also measured, by trypsinizing adherent cells, pelleting cells, resuspending pellets in equal parts of RPMI media and Trypan blue, and counting. Detachment was measured by comparing the number of proliferating cells and detached cells in the presence or absence of OSM, and fold detachment was calculated. Statistical analysis was performed using GraphPad Prism software for 1 way ANOVA tests.
Wound healing assay
A wound healing assay was used to measure mobility of breast cancer cell with or without OSM treatment. MCF-7 luc and MDA-MB-231 luc shCD44 and shNTC control cells were plated at 200,000 cells per well in a 6-well plate with 10% FBS RPMI media. Once cells were 80-85% confluent, a scratch was made with a sterile p1000 micropipette tip. Wells were washed with PBS and then 10% media was placed on each well with or without OSM (25 ng/mL). Photomicrographs were taken at 72 hrs. The area of each scratch was measured using ImageJ and foldmigration was assessed. Statistical analysis was performed using GraphPad Prism software for 1 way ANOVA tests.
Chemical inhibitor
A MMP inhibitor (GM6001; Santa Cruz Biotechnology), was added to the cell growth media (10 nM) 2 days before cytokine treatment in serum-free media; followed by the addition of complete media and OSM for 2 more days.
Results
OSM induces EMT and CD44
+ /CD24
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BCSC population
The EMT process is commonly studied in vitro using ER+ human breast cells because, compared to ER-cells, they are less aggressive, phenotypically epithelial, and respond Figure 1D ), and in T47D cells from 1% to over 4% ( Figure 1E 
OSM induces both CD44 expression and cleavage
CD44 expression fluctuates during tumor progression and metastasis. Our studies showed that OSM induced CD44 expression at the protein level over time in ER+ but not ER-cells (Figure 2 ). Treatment of ER+ MCF7 cells with OSM (25 ng/mL) for 24, 48, and 72 hrs resulted in an increase in high molecular weight CD44 alternatively spliced (top panels) isoforms and low molecular weight cleavage products (lower panels) at each time point (Figure 2A and B) , as measured by Western blot analysis of whole cell lysates using an antibody specific to the cytoplasmic fragment of CD44. For ER+ T47D cells, OSM-induced CD44 high molecular weight CD44 isoforms were most prevalent at 48 and 72 hrs (Figure 2C and D). CD44 expression in the more aggressive ER-MDA-MB-231 cells showed a high basal level, which did not change in the presence of OSM during the same time period (Figure 2E and F) . In these experiments, we observed an OSM-induced increase of high molecular weight bands larger than the CD44s (70-85 kDa) band.
To support our finding that OSM induced CD44s and variant CD44 protein expression in ER+ breast cancer cells, we investigated OSM-induced CD44 mRNA levels by qRT-PCR. While a non-significant increase in OSMinduced CD44s expression was observed at 8 hrs in MCF-7 cells (Figure S2A ), OSM did not significantly induce the mRNA levels of individual CD44 variants (v2 through v10) at the 8 hr time point, it was observed that OSM slightly increased CD44 variants ( Figure S2B) . Together, these studies suggest that while OSM does not induce CD44 mRNA expression, it does result in increased levels of CD44s and variant proteins. These results showed that in ER+ breast cancer cells, which have a lower basal level of CD44 expression, OSM increased the expression of high molecular weight CD44 isoforms, while the more aggressive TNBC cells that express high basal levels of CD44, do not respond to OSM.
Proteolytic cleavage of CD44 by matrix metalloproteinases (MMPs) and γ-secretase occurs in close proximity to the cell membrane and produces low molecular CD44 fragments. Specifically, CD44 is first cleaved by MMP-9 and subsequently undergoes a second cleavage by γ-secretase producing a smaller fragment known as the intracellular domain (ICD) CD44. 68 Our lab has previously shown that OSM induces MMP activity in breast tumor cells. 21 T47D
cells treated with the global MMP inhibitor GM6001 for 48 hrs followed by OSM (25 ng/mL) treatment for 48 hrs decreased the amount of OSM-induced MMP cleavage of CD44 ( Figure S3A and B). Proteolytic activity of MMP cleavage produces molecular weight bands of 30 kDa and smaller. Inhibiting OSM-induced MMP activity decreased OSM induces an increased mesenchymal phenotype and a decrease in E-cadherin expression, as measured by immunofluorescence using antibodies for E-cadherin and actin (63× magnification). (B) MCF-7 cells were treated with OSM (25 ng/mL) for 1 hr, and qPCR was performed with primers for the EMT transcription factors Slug and Snail (*P<0.05, unpaired t-test). (C) MCF-7 cells were treated with OSM (25 ng/mL) for 24, 48 and 72 hrs, and cell lysates were assessed by Western blot analysis for E-cadherin and α-catenin (D and E). ER+ MCF-7 and T47D cells were treated with OSM (25 ng/mL) for 72 hrs before flow cytometry was performed. In T47D cells, OSM induces the CD44 + /CD24 − BCSC population 3-fold, while a small non-significant increase was seen in MCF-7 cells. **P<0.01, *P<0.05, unpaired t-test.
the amount of cleaved CD44. To summarize, OSM promotes EMT in ER+ breast cancer cells, increases CD44 expression, and induces proteolytic cleavage of CD44, presumably through OSM-induced MMP activity.
OSM-induced EMT is independent of CD44
The relationship between OSM-driven EMT and OSMupregulation of CD44 expression was explored by establishing stable ER+ MCF-7 luc and ER-MDA-MB-231 luc cells with CD44 expression knockdown using shCD44 lentiviral transduction. MCF-7 luc-shCD44 cells showed a 70% reduction in CD44s expression by Western blot analysis compared to control shNTC (non-targeting control) cells, while MDA-MB-231 luc-shCD44 cells showed over an 80% reduction in CD44s ( Figure 3A and B) . Next, we investigated two transcription factors, Slug and Snail, which have been shown to drive EMT by repressing E-cadherin expression that results in loss of cell-cell adhesion. MCF-7 luc-shCD44 and control shNTC cells were treated with OSM (25 ng/mL) for 1 hr 
(ER+), and (B) quantification of (A). (C) CD44 expression in T47D (ER+), and (D) quantification of (C). (E) CD44 expression in MDA-MB-231 (ER-), and (F). quantification of (E)
. All OSM treatment time points were compared to the corresponding non-treatment time points after normalizing to ß-actin. Unpaired t-tests were performed for each time point. **P<0.01, *P<0.05. and qRT-PCR was performed. As expected, OSM increased both Slug and Snail over 1.5-fold compared to no treatments in control MCF-7 luc-shNTC cells ( Figure 3C and D) . However, OSM treatment of MCF-7 luc-shCD44 cells resulted in no significant change in Slug expression compared to control shNTC cells, suggesting that CD44 is not involved in the upregulation of Slug by OSM ( Figure 3C ). Interestingly, CD44 knockdown resulted in a significant increase in OSM-induced Snail expression compared to control shNTC to cells, suggesting that the absence of CD44 increased OSM-induced Snail ( Figure 3D ). OSM-repressed E-cadherin expression during EMT was observed by confocal microscopy immunostaining in MCF-7 luc-shCD44 and shNTC cells ( Figure 3E ). In the presence of OSM (25 ng/mL) for 72 hrs, shNTC and shCD44 cells both showed a reduction in the cell-cell adhesion protein, Ecadherin ( Figure 3E ). Photomicrographs of MCF-7 lucshCD44 and shNTC cells treated with OSM for 72 hrs were also taken to observe the phenotypic EMT process ( Figure 3F ). Although both cell lines underwent characteristic EMT processes, the MCF-7 shCD44 cells appeared to form much tighter colonies prior to OSM treatment. Together, these results suggest that OSM-induced EMT takes place independently of CD44 in ER+ MCF-7 luc cells.
MCF-7 luc
OSM-induced tumor cell detachment is dependent on CD44
As part of the metastatic cascade, tumor cells must detach from their established three-dimensional location. We have previously shown OSM to be a strong inducer of tumor cell detachment, especially in ER+ breast cancer cells. 21 MCF-7 luc-shCD44 and MDA-MB-231 luc-shCD44 cells were treated with OSM (25 ng/mL), and fold-detachment was measured over a 5-day period (Figure 4 ). OSM induced a 1.8-to 3-fold increase in cell detachment using the less aggressive ER+ MCF-7 luc-shNTC cells compared to untreated cells ( Figure 4A ; left). When MCF-7 luc-shCD44 cells were treated with OSM, no significant increase in tumor cell detachment was measured at days 1 and 3 ( Figure 4A ; right), suggesting that knockdown of CD44 eliminated or delayed the ability of OSM to induce ER+ MCF-7 breast tumor cell detachment. The more aggressive ER-MDA-MB-231 luc-shNTC control cells did not detach in the presence or absence of OSM ( Figure 4B; left) . Interestingly, MDA-MB-231 lucshCD44 cells treated with OSM for 5 days showed a 6-fold increase in tumor cell detachment compared to control cells, thus mimicking MCF-7 luc shNTC cells (Figure 4B ; right). Therefore, it appears that MDA-MB-231 lucshCD44 cells reverted from aggressive and basically OSM-unresponsive cells to less aggressive cells that responded to OSM when CD44 expression was reduced. Together, these results suggest that OSM-induced ER+ MCF-7 tumor cell detachment is dependent on CD44 expression.
OSM-induced tumor cell migration is dependent on CD44
Following EMT, a tumor cell must utilize two-dimensional movement in order to initiate invasion and metastasis. Wound healing assays were performed using ER+ MCF-7 luc-shCD44 and MDA-MB-231 luc-shCD44 cells to quantitate tumor cell migration. MCF-7 luc shNTC cells treated with OSM (25 ng/mL) for 3 days demonstrated a slight 1.5-fold increase in migration compared to untreated cells ( Figure 5A ), Importantly, MCF-7 luc-shCD44 cells migrated to a significantly less extent when compared to shNTC control cells in the presence of OSM ( Figure 5A , black bars). When treated with OSM for 3 days, the ER-MDA-MB-231 luc-shCD44 cells showed a nearly 2.5-fold reduction in the number of migrating cells compared to MDA-MB-231 lucshNTC cells ( Figure 5B , black bars). This striking difference reiterates the importance of CD44 in tumor cell migration for aggressive ER-breast cancer cells, while demonstrating a role for OSM-induced CD44 in ER+ MCF-7 cell migration. In conclusion, OSM-induced CD44 appears to be important in tumor cell detachment and migration, both necessary for tumor cells undergoing metastasis.
Discussion
Breast cancer metastasis requires that individual tumor cells undergo multiple changes and survive in diverse environments before reaching a secondary location and expanding. It is speculated that the metastatic cascade consists of a number of specifically ordered and timed events that must take place, starting with EMT and ending in mesenchymal-epithelial transition (MET) and clonal expansion of each metastasis. CD44 has been previously shown to be an important driver of invasion and the metastatic process. In this research, we show that OSM induces an EMT that is not dependent on CD44. Rather, OSM-induced CD44 is necessary for breast tumor cell detachment and migration regulated by OSM.
Our results presented here compare to previously published data on OSM-induced EMT by showing a decrease in epithelial markers and a phenotypic change to cells in culture. 69 We also demonstrated the ability of OSM to increase a BCSC phenotype, which has been previously published. 70 OSM-induced breast tumor cell detachment has also been published. 71 In this study, we show for the first time that OSM induces alternatively spliced and cleaved CD44 protein expression. Other cytokines have been shown to increase metastatic characteristics in breast cancer, and here we showed that OSM increased CD44 expression, but did not affect its alternative splicing. Previous studies have shown cytokines such as TGF-β are strong inducers of CD44. 72, 73 Our results show OSM induces CD44 expression in a similar manner to that of TGF-β by increasing CD44 expression and subsequent CD44 cleavage. Although ERcells did not respond to OSM in the same manner of ER+, PR+, HER2-luminal A cells, it was shown CD44 is actually expressed at such a high basal level that an increase was not observed and therefore TNBC MDA-MB-231 luc cells were not used to study induction of CD44 via OSM, as other publications have shown the same using this ER-cell line. 74 Furthermore, OSMinduced MMP-9 CD44 cleavage was reduced by using the non-specific MMP inhibitor GM6001 as shown by the reduction of low molecular weight bands. Our lab and others have previously shown that OSM induces the expression of a family of MMPs. 75, 76 Our lab was not able to show that OSM was capable of inducing secretase, suggesting that OSM's ability to cleave CD44 is limited to MMP activity. The connection between OSM-induced EMT and CD44 expression was examined using MCF-7 luc and MDA-MB-231 luc shCD44 cell lines with knockdown expression of CD44. Non-targeting control (shNTC) cell lines responded similarly to parental MCF-7 cells in terms of OSM-induced EMT, transcriptional activity, and EMTrelated proteins. In CD44 knockdown cell lines, EMT occurred following OSM treatment, but the knockdown of CD44 in MCF-7 luc cells displayed less detachment compared to control cell lines. MDA-MB-231 luc shCD44 cells detached at a much larger number compared to control. Migration was reduced in both MCF-7 luc and MDA-MB-231 luc shCD44 cells compared to control shNTC cells suggesting CD44 contributes to migration during metastasis. Furthermore, with reduced CD44 expression, MCF7 luc cells grew and responded much differently compared to the control cells in terms of morphological changes as they appeared to contain an increased number of rounded up cell populations and they also took much longer to adhere to cell culture flasks. These findings suggest the potential role for CD44 as an adhesion molecule and cell-cell attachment protein. MCF-7 luc-shCD44 cells also grew in much tighter colonies, with small groups broken away from the primary colony following 72 hrs of OSM treatment. Cells that broke away from the primary colony following OSM treatment did not undergo an EMT as they appeared to be display tighter cell-cell adhesion. All of this indicates that CD44 was not directly responsible for an early event in metastasis, EMT. Although previous studies have displayed a correlation between an increase in CD44 expression and EMT, 77 here we show they are ordered events as CD44 participates in later metastatic events, but not in the initial EMT. Metastatic events such as cellular detachment and migration have often thought to be steps necessary in the early to middle stages of metastasis. In the presence of OSM, control cells migrated more than shCD44 cells and a similar trend was observed for detachment. Aggressive cells like the MDA-MB-231 luc cells do not detach in the presence of OSM, but the knockdown of CD44 promoted OSM-induced detachment. The opposite was shown in the less aggressive MCF-7 luc cells where OSMinduced detachment was reduced in the shCD44 group suggesting CD44 is used by less aggressive cells to become more metastatic. Others have shown cytokines such as TGF-β increase detachment and migrationbut our data shows both events can occur through OSM signaling and the expression of CD44.
Together our studies show the binding of OSM to its receptor leads to the promotion of EMT, migration, and detachment in less aggressive ER+ breast tumor cells ( Figure 6 ). OSM signaling also leads to an increase in the upregulation of CD44 expression and CD44 cleavage in these cells. OSM-induced CD44 cleavage via MMP Figure 6 OSM signaling induces an EMT and upregulates CD44 and cleavage of CD44 in breast tumor cells: Once bound to its receptor, OSM induces cells to undergo EMT and subsequent detachment and migration. OSM signaling increases expression of the transmembrane protein CD44 and also cleavage via MMPs. OSMinduced CD44 is involved in migration and detachment as well as docking, which is the step immediately before extravasation during the metastatic cascade.
proteolytic action promotes migration and detachment in less aggressive cells thus making them more aggressive. CD44 knockdown expression in highly aggressive MDA-MB-231 luc cells allows for the cells to become receptive to OSM and adapt to ER+ cell-like sequence of metastatic events.
Conclusion
The results presented in this manuscript demonstrate that the inflammatory cytokine OSM promotes CD44 expression in ER+ breast cancer cells. Furthermore, this CD44 seems to play a central role in OSM-induced tumor cell detachment but not in EMT. Together, our results suggest that the regulation of CD44 by OSM is important for at least part of the metastatic cascade in ER+ breast cancer. These findings should provide useful in future studies of human metastatic breast cancer with the goal of developing potential therapeutics to reduce mortality rates.
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